Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols
Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.
Who we are
Entheon is in a unique position to challenge the narrative – and expectations – around addiction recovery.
Leveraging emerging bio-technology, we are pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorder. Focusing primarily on the powerful DMT molecule, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Learn More About Entheon
Investors
